Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Decraene, Brecht; Yang, Yihan; Smet, Frederik De; Garg, Abhishek D.; Agostinis, Patrizia; Vleeschouwer, Steven De

doi:10.1038/s41435-021-00161-5

Cited by 33 publications

(25 citation statements)

References 178 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICD, a novel concept linking dying cancer cells with the immune system, is a form of cell death that leads to the regulation and activation of the immune response ( 36 ). The concomitant ROS production and endoplasmic reticulum stress within the ICD process activate the exposure and release of DAMPs in the tumor microenvironment, which is able to potentiate immune response ( 37 ). Currently, there is no study reporting the prognosis and immunotherapy of patients with GBM based on ICD gene signatures.…”

Section: Discussionmentioning

confidence: 99%

Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM

Feng

Liang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immunogenic cell death (ICD) is a type of cell death that leads to the regulation and activation of the immune response, which is marked by the exposure and delivery of damage‐associated molecular patterns (DAMPs) in the tumor microenvironment. Accumulating evidence has revealed the significance of ICD-related genes in tumor progression and therapeutic response. In this study, we obtained two ICD-related clusters for glioblastoma (GBM) by applying consensus clustering, and further constructed a risk signature on account of the prognostic ICD genes. Based on the risk signature, we found that higher risk scores were associated with worse patient prognosis. Besides, the results illustrated that ferroptosis regulators/markers were highly enriched the high-risk group, and ferroptosis were correlated with cytokine signaling pathway and other immune-related pathways. We also discovered that high-risk scores were correlated to specific immune infiltration patterns and good response to immune checkpoint blockade (ICB) treatment. In conclusion, our study highlights the significance of ICD-related genes as prognostic biomarkers and immune response indicators in GBM. And the risk signature integrating prognostic genes possessed significant potential value to predict the prognosis of patients and the efficacy of ICB treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM

Feng

Liang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…US-based BBB disruption, therefore, can both enhance CNS penetration of PTX and improve survival [ 176 ]. Additionally, paclitaxel has been recently identified as an inducer of immunogenic cell death, a form of cell death that directly promotes antitumor immunity [ 176 ], and as a result, BBB-mediated delivery of paclitaxel may enhance immunotherapies for GBM [ 177 ].…”

Section: Making Things Hot: Promoting T-cell Infiltration Into Gbmmentioning

confidence: 99%

Next Steps for Immunotherapy in Glioblastoma

Cao

Wainwright

Lee-Chang

et al. 2022

Cancers

View full text Add to dashboard Cite

Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.

show abstract

“…Immunogenic cell death (ICD) is a more recently discovered cell death modality that involves specific, timed changes to the cell surface (CRT expression) followed by release of soluble DAMPs (e.g., HMGB1, HSP). Importantly, this increases the immunogenicity of dying/dead cancer cells, and has the ability to potentiate adaptive immune responses and target residual cancer cells/tissues [13,14].…”

Section: Introduction 1oncolytic Virusesmentioning

confidence: 99%

Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword

Blitz

Kappel

Geßler

et al. 2022

IJMS

View full text Add to dashboard Cite

Oncolytic virotherapy is a rapidly progressing field that uses oncolytic viruses (OVs) to selectively infect malignant cells and cause an antitumor response through direct oncolysis and stimulation of the immune system. Despite demonstrated pre-clinical efficacy of OVs in many cancer types and some favorable clinical results in glioblastoma (GBM) trials, durable increases in overall survival have remained elusive. Recent evidence has emerged that tumor-associated macrophage/microglia (TAM) involvement is likely an important factor contributing to OV treatment failure. It is prudent to note that the relationship between TAMs and OV therapy failures is complex. Canonically activated TAMs (i.e., M1) drive an antitumor response while also inhibiting OV replication and spread. Meanwhile, M2 activated TAMs facilitate an immunosuppressive microenvironment thereby indirectly promoting tumor growth. In this focused review, we discuss the complicated interplay between TAMs and OV therapies in GBM. We review past studies that aimed to maximize effectiveness through immune system modulation—both immunostimulatory and immunosuppressant—and suggest future directions to maximize OV efficacy.

show abstract

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Cited by 33 publications

References 178 publications

Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM

Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM

Next Steps for Immunotherapy in Glioblastoma

Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword

Contact Info

Product

Resources

About